EGFR and neoplasm: Although tumor biomarker analyses from the ZODIAC study [40] suggested that consistent trends toward improved OS, PFS, and objective response rate for patients with EGFR gene copy number (FISH+) or EGFR mutation status (MT) tumors were seen with vandetanib group plus docetaxel versus docetaxel alone, it is not clear whether vandetanib has a potential advantage in patients with specific biomarkers as compared with single EGFR signaling pathways inhibition therapy (e.g. erlotinib).